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Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality
approach, depending on the stage and biology of the tumour and the acceptance and tolerance
of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy,
chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation
planning and delivery, and genomics, and the development of novel systemic therapy agents alongside
their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this
Special Issue entitled, ‘Treatment strategies and survival outcomes in breast cancer’, a number of
original research articles are included covering a diversity of studies, from pre-clinical and translational
biomarker studies to clinical trials and population-based studies. They evaluated survival and other
outcomes, including quality of life, in the context of pre-diagnosis (screening), as well as early and
advanced stages of breast cancer.
With the established survival benefits of prophylactic mastectomy in women with BRCA genetic
mutations, the procedure is increasingly being performed on the contralateral breast following diagnosis
of breast cancer. Teoh et al. conducted a review of the literature which mostly consisted of retrospective
studies with less than optimal data quality [1]. The evidence suggests a reduction of incidence of
contralateral breast cancer following the procedure in those with ‘high risk’, notably those with BRCA
genetic mutations, whereas survival benefits are uncertain. The overall benefits in other risk categories
are even more doubtful. In the area of pre-invasive cancer, Sieuwerts et al. observed in cases of ductal
carcinoma in situ an upregulation of APOBEC3B, which was previously seen in invasive carcinoma and
known to be associated with poor prognosis, suggesting its potential role in early carcinogenesis [2].
There are two studies on screening. Heller looked at approximately 993,000 individuals using a
national database, aiming to see why screening did not appear to decrease the incidence of stage IV
breast cancer [3]. They found that among those diagnosed up front with stage IV disease, 37.6% had
aggressive tumours as compared to 5.1% in those with stage 1 disease, suggesting that the two groups
are from different populations with different tumour phenotypes. Regarding screening, over-diagnosis
has been coined as the main concern. Fann et al. evaluated the 15-year adjusted cumulative survival of
breast cancer in a cohort in Sweden, and noted that the majority of survivors could be attributed to cure
arising from screening and subsequent treatments [4]. According to their interpretation, over-diagnosis
had minimal contribution.
For primary breast cancer, Corradini et al. analysed the oncological outcomes of 7565 cases
of breast cancer in a case-controlled cohort study comparing breast conserving surgery followed
by radiotherapy with mastectomy, showing that the former was associated with better recurrence
control and survival, and as such recommended physicians to encourage women to receive such
treatment [5]. While the findings are interesting, provocative and continue to be reassuring in terms
of the efficacy of breast conserving surgery, their applications must be cautioned. The findings have
not been consistently shown by randomised controlled trials and must be further investigated before
a change in practice is implemented. This Special Issue also contains a few studies related to breast
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cancer in older patients. In a population-based registry study in the Netherlands, survival in these
patients was found to be poorer when compared to their younger counterparts, and the observation
was shown to be associated with a proportionately reduced use of surgery and increased use of primary
endocrine therapy [6]. As discussed by the researchers, this phenomenon has been picked up in
other studies and changes in treatment guidelines have since been made. While surgery is now the
primary treatment of choice in this population as in the younger one, alternative treatments such as
primary endocrine therapy may still be appropriate, especially in patients with competing causes of
death due to significant comorbidities. Given this, and other needs to appropriately select treatments,
including primary and adjuvant therapies in this challenging population, biomarker studies play a
very important role in translational research. Three such biomarkers—LKB1 [7] and cytoplasmic cyclin
E [8] (poor prognostic in the older (>70 years) population), and HDAC5 [9] (poor prognostic in the
very young (<35 years) patients)—have been found to be associated with age. Furthermore, other
conventional and emerging prognostic and predictive factors were investigated and reported in this
Special Issue. Kim et al. highlighted the use of high lymph-node ratio following axillary surgery as an
indicator of poor prognosis and the need for radiotherapy to the supraclavicular fossa in a retrospective
study [10]. However, sentinel node biopsy has now become the standard axillary staging procedure,
making the precise calculation of the ratio difficult. As a result, its potential clinical application is likely
to be limited. In addition, Abdel-Fatah studied an emerging biomarker, ERCC1, a DNA excision repair
protein, and noted its potential prognostic significance and ability to predict response in neoadjuvant
chemotherapy [11]. In a different study using a cell line model, Gaule et al. identified the potential role
of combining dasatinib and a c-Met inhibitor, in order to combat dasatinib resistance in triple negative
breast cancer [12].
In the context of metastatic breast cancer, the Special Issue contains two pieces of work focusing on
important new targeted therapies currently licensed for clinical use, CDK4/6 inhibitors and anti-HER2
therapies. Rossi et al. carried out a network meta-analysis comparing the combination use of individual
CDK4/6 inhibitors with fulvestrant or an aromatase inhibitor [13]. They found that CDK4/6 inhibitors
have similar efficacy when combined with an aromatase inhibitor in the first-line treatment of hormone
receptor positive disease, and are superior to either endocrine agent as monotherapy, regardless of any
other patient or tumour characteristics. While this may be seen as reassuring for those who are strong
supporters of using such a combination despite the concerns on increased toxicity, the authors admitted
the limitations of their meta-analysis, including not using actual patient data, the lack of uniformity
in terms of prior use of endocrine therapy, and the fact that some trials employed non-standard
fulvestrant dose (250 mg, rather than 500 mg). On the other hand, the PRAEGNANT Real-World Breast
Cancer Registry study reviewed the landscape of using anti-HER2 therapies [14]. Both novel therapies
(pertuzumab/trastuzumab and T-DM1) are utilised in a high proportion of HER2 positive breast cancer
patients. Most patients were found to receive T-DM1 after pertuzumab/trastuzumab in a real-world
setting. The Special Issue contains two other interesting studies regarding this disease stage. Keup et al.
advocated a ‘comprehensive’ liquid biopsy, including both cell-free DNA mutational and circulating
tumour cell transcriptional analyses, which could increase the chance of identifying actionable targets
at which to direct therapeutic strategies [15]. Pelizzari identified the change in plasma LDH levels as a
potential cost-effective biomarker of prognosis in the early course of systemic therapy [16]. According
to the results of their study, patients who maintained elevated LDH levels after 12 weeks of first-line
treatment experienced worse survival outcomes when compared to those with stable normal LDH
levels, even after adjustment for other prognostic factors.
Finally, as opposed to survival outcomes, Hong et al. carried out a systematic review and
meta-analysis of randomised controlled trials to investigate quality of life as another important
treatment outcome for breast cancer [17]. Their work showed that exercise interventions improved
quality of life and that the ‘time of session’ (longer than 45 minutes) appeared to be crucial in achieving
significant improvement.
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